In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana's main ingredient, THC, reduces agitation in patients with Alzheimer's by an average of 30%. The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as delirium or seizures. Results of the eight-year clinical trial were presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, on Sept.
26. These new findings represent eight years of work dedicated to people who have Alzheimer's as well as their caregivers. Agitation is one of the most distressing symptoms of Alzheimer's dementia, and we are pleased to make positive strides forward in treatment of these patients.
" Paul Rosenberg, M.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and co-principal investigator for this study Alzheimer's disease is the most common neurodegenerative disease in the United States, with an estimated 6.
7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060.
Agitation is difficult to manage. It is defined as excess motor activity (pacing or repetitive movements), verbal aggression and/or physical.
